Literature DB >> 17922727

CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.

A Agren-Wilsson1, A Lekman, W Sjöberg, L Rosengren, K Blennow, A T Bergenheim, J Malm.   

Abstract

BACKGROUND - To evaluate cerebrospinal fluid (CSF) markers for neuronal degeneration and demyelination in idiopathic normal pressure hydrocephalus (INPH), subcortical arteriosclerotic encephalopathy (SAE), and neurologically healthy subjects. METHODS - Lumbar CSF concentrations of sulfatide, neurofilament protein light (NFL), total-tau (T-tau), hyperphosphorylated tau (P-tau), and beta-amyloid(1-42) (Abeta42) were analyzed in 62 INPH patients, 26 SAE patients, and 23 neurologically healthy controls. In INPH patients, samples before and after shunt surgery were analysed. RESULTS - The CSF concentration of NFL was elevated in INPH and SAE compared with the controls, and levels of T-tau, P-tau, and Abeta42 were lower in INPH compared with SAE and controls. No difference was seen for sulfatide. All markers except Abeta42 were significantly elevated after shunt surgery. CONCLUSIONS - The most striking finding was the power of the combined pattern of NFL, P-tau, and Abeta42 in distinguishing between the clinical diagnoses of INPH, SAE, and neurologically healthy elderly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922727     DOI: 10.1111/j.1600-0404.2007.00890.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  36 in total

Review 1.  A review of cognitive impairment and differential diagnosis in idiopathic normal pressure hydrocephalus.

Authors:  Marta Picascia; Roberta Zangaglia; Sara Bernini; Brigida Minafra; Elena Sinforiani; Claudio Pacchetti
Journal:  Funct Neurol       Date:  2015 Oct-Dec

2.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Vascular risk factors in INPH: A prospective case-control study (the INPH-CRasH study).

Authors:  Hanna Israelsson; Bo Carlberg; Carsten Wikkelsö; Katarina Laurell; Babar Kahlon; Göran Leijon; Anders Eklund; Jan Malm
Journal:  Neurology       Date:  2017-01-06       Impact factor: 9.910

4.  Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus.

Authors:  Neill R Graff-Radford
Journal:  Neurology       Date:  2014-10-21       Impact factor: 9.910

Review 5.  Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus.

Authors:  Tommaso Schirinzi; Giulia Maria Sancesario; Giulia Di Lazzaro; Alessio D'Elia; Paola Imbriani; Simona Scalise; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2018-01-20       Impact factor: 3.575

Review 6.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Harald Hampel; Michael Weiner; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

7.  Cerebrospinal fluid dynamics and discordant amyloid biomarkers.

Authors:  Jonathan Graff-Radford; David T Jones; Heather J Wiste; Petrice M Cogswell; Stephen D Weigand; Val Lowe; Benjamin D Elder; Prashanthi Vemuri; Argonde Van Harten; Michelle M Mielke; David S Knopman; Neill R Graff-Radford; Ronald C Petersen; Clifford R Jack; Jeffrey L Gunter
Journal:  Neurobiol Aging       Date:  2021-11-01       Impact factor: 4.673

8.  Cerebrospinal fluid analysis should be considered in patients with cognitive problems.

Authors:  Henrik Zetterberg; Niklas Mattsson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-14

9.  A panel of neuron-enriched proteins as markers for traumatic brain injury in humans.

Authors:  Robert Siman; Nikhil Toraskar; Antony Dang; Elizabeth McNeil; Micheal McGarvey; Justin Plaum; Eileen Maloney; M Sean Grady
Journal:  J Neurotrauma       Date:  2009-11       Impact factor: 5.269

Review 10.  Fluid biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Henrik Zetterberg; Anne M Fagan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.